Since there are so many options available to treat advanced renal cell carcinoma, it may be helpful to seek out additional opinions about the best possible care.

Clinically significant developments in RCC presented at ASCO GU, including insights into the growing importance of HIF-2α inhibition, are discussed by Dr Brian Rini of Vanderbilt University.

Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancerTransformative moment in ...

For oncologists navigating the rapidly evolving landscape of renal cell carcinoma (RCC), the data presented at the 2026 ASCO ...

The US Food and Drug Administration (FDA) has approved belzutifan (Welireg) for adults with advanced renal cell carcinoma following progression on a PD-1/L1 inhibitor and a vascular endothelial growth ...

LITESPARK-011 demonstrated improved progression-free survival with the combination of belzutifan plus lenvatinib vs ...

The CAIX targeting radiotracer 68 Ga-C1 was developed and validated through in vitro assays. Initially, the investigators ...

Merck (NYSE:MRK) reported new Phase 3 data for belzutifan based WELIREG regimens in renal cell carcinoma, showing meaningful improvements when paired with KEYTRUDA or LENVIMA. The company has filed ...

The lead singer of the band 3 Doors Down shared Wednesday that he has stage 4 kidney cancer that has spread to his lung. In an Instagram video, Brad Arnold said he had been feeling sick for a few ...

Lubbock Fire Rescue announced that one of its Lieutenants received a life-saving early cancer diagnosis following his annual physical.